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Lessons from Botswana’s HIV/AIDS treatment programme
The report by Mansour Farahani and colleagues1 in 
The Lancet Global Health of 9-year outcomes of the 
antiretroviral therapy (ART) programme in Botswana 
is a welcome addition to the scientiﬁ c literature on ART 
programmes. It provides national-level data for more 
than 126 000 patients who initiated ART from 2002 to 
2010. Botswana was the ﬁ rst country in sub-Saharan 
Africa to make a strong national commitment to scaling 
up treatment to the entire eligible population. There 
was early commitment from the commercial sector 
and the national government to provide resources for 
treatment. Donor support quickly followed. As a result, 
Botswana achieved very high coverage, 80–90%, of 
those eligible for treatment as early as 2005. The eﬀ ect 
of this high coverage was an estimated decrease in 
AIDS deaths of more 50% from 2002 to 2006.2 The 
programme has maintained high coverage even as 
eligibility has expanded. Conﬁ rmation of this high 
coverage comes from data presented by Farahani and 
colleagues showing that the median CD4 cell count at 
treatment initiation rose from 101 cells/μL (IQR 44–156) 
in 2002, to 191 cells/μL (115–239) by 2010. The increase 
in CD4 count at initiation contributed to the decrease in 
overall mortality of those in their ﬁ rst year of treatment 
from 29% (51 of 171) of patients in the ﬁ rst year of the 
programme to 3% (349 of 11 679) in 2009. 
Farahani and colleagues report that mortality for 
patients receiving ART was highest in the ﬁ rst few months 
of treatment and then declined sharply with longer time 
on treatment. This ﬁ nding is consistent with patterns 
shown by the International Epidemiologic Databases 
to Evaluate AIDS (IeDEA) Consortium reporting on 
mortality among 123 000 patients in treatment cohorts 
in several diﬀ erent countries.3 For southern Africa the 
IeDEA Consortium estimates that mortality in the ﬁ rst 
year of treatment is more than double the rate for those 
on treatment for more than 2 years.3 The Botswana 
data show an even steeper gradient in mortality with 
12·8 deaths per 100 person-years (95% CI 12·4–13·2) in the 
ﬁ rst 3 months of treatment, 3·46 deaths per 100 person-
years (3·25–3·69) after 6 months of treatment, and only 
1·16 deaths per 100 person-years (1·12–1·20) in the 
second year of treatment. This ﬁ nding provides strong 
justiﬁ cation for earlier treatment initiation.
As with most analyses of this type, the results are 
aﬀ ected by assumptions about what happened to 
patients who were lost to follow-up, who constituted 
12% (15 270 of 126 263) of the patients in the database. 
The reported mortality is based on documented deaths 
of patients receiving ART and patient-years of follow-
up and thus is likely to underestimate total mortality. 
Farahani and colleagues estimate that if 60% of those 
who were lost to follow-up had died, then the overall 
mortality would increase from 8% (10 230 of 126 263) 
to 11–13%.
Botswana has been a leader in showing that high-
quality treatment and programmes to prevent mother-
to-child transmission (95% coverage in 20124) can 
be implemented at scale by national programmes in 
sub-Saharan Africa. Sustaining this success will require 
meeting new challenges, particularly meeting the rising 
costs of the programme with even larger contributions 
from the national government and identifying and 
initiating people on treatment earlier, at CD4 counts of 
up to 500 cells/μL. Meeting these challenges will provide 
substantial beneﬁ ts in terms of reduced mortality, 
fewer new HIV infections, fewer orphaned children, and 
future savings from averting infections (saving future 
treatment costs) and productivity losses. 
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